Valvular & structural heart diseaseCohort study
Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation
- Retrospective cohort study
- double centre
Authors' conclusion
CKM is highly prevalent in patients undergoing TAVI. Higher CKM condition burden was associated with adverse outcomes.
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI), 2011–2024; CKM defined by atherosclerotic cardiovascular diseases (ASCVD), chronic kidney disease (CKD) and diabetes mellitus (DM)
- Participants
- 5,834 patients
- Exposure
- CKM conditions vs no CKM conditions
- Outcome
- Prevalence of CKM and its association with procedural success, bleeding, permanent pacemaker implantation and 1-year mortality
Main finding
As reported in the abstract
CKM prevalence and 1-year mortality · 1 year
- 2 CKM conditions
- HR 1.40; P = 0.030
- 3 CKM conditions
- HR 1.88; P < 0.001
- CKM prevalence
- 5,280 (90%)
Observational data: associations, not effects.
Further findings
Procedural success
- Highest with no CKM conditions, then 1 and 2; worst with 3 CKM conditions
- P = 0.002
All-cause mortality, adjusted · 1, 2 and 5 years
- 3/3 CKM conditions remained associated with increased all-cause mortality after adjustment
Safety
| Outcome | Estimate | P value |
|---|---|---|
| Permanent pacemaker implantation | OR 1.45 | P = 0.02 |
| Major bleeding | HR 1.24 | P = 0.328 |
Original publication
Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation. Eur J Heart Fail. Published 13 March 2026. doi:10.1093/ejhf/xuag075
Summarised from the published abstract; every number is checked against it